CR20130533A - INHIBIDORES POTENTES Y SELECTIVOS DE NAv1.3 y NAv1.7 - Google Patents

INHIBIDORES POTENTES Y SELECTIVOS DE NAv1.3 y NAv1.7

Info

Publication number
CR20130533A
CR20130533A CR20130533A CR20130533A CR20130533A CR 20130533 A CR20130533 A CR 20130533A CR 20130533 A CR20130533 A CR 20130533A CR 20130533 A CR20130533 A CR 20130533A CR 20130533 A CR20130533 A CR 20130533A
Authority
CR
Costa Rica
Prior art keywords
powerful
selective inhibitors
inhibitor
inhibitors
composition
Prior art date
Application number
CR20130533A
Other languages
English (en)
Spanish (es)
Inventor
Justin K Murray
Leslie P Miranda
Stefan I Mcdonough
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR20130533A publication Critical patent/CR20130533A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Insects & Arthropods (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CR20130533A 2011-03-16 2013-10-16 INHIBIDORES POTENTES Y SELECTIVOS DE NAv1.3 y NAv1.7 CR20130533A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161453492P 2011-03-16 2011-03-16
US201261608088P 2012-03-07 2012-03-07

Publications (1)

Publication Number Publication Date
CR20130533A true CR20130533A (es) 2014-01-09

Family

ID=45895479

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130533A CR20130533A (es) 2011-03-16 2013-10-16 INHIBIDORES POTENTES Y SELECTIVOS DE NAv1.3 y NAv1.7

Country Status (24)

Country Link
US (2) US9340590B2 (enExample)
EP (1) EP2686340A2 (enExample)
JP (2) JP2014509859A (enExample)
KR (1) KR20140145947A (enExample)
CN (1) CN103930437A (enExample)
AP (1) AP2013007173A0 (enExample)
AR (1) AR088413A1 (enExample)
AU (1) AU2012228990B2 (enExample)
BR (1) BR112013023674A2 (enExample)
CA (1) CA2830065A1 (enExample)
CL (1) CL2013002673A1 (enExample)
CO (1) CO6821886A2 (enExample)
CR (1) CR20130533A (enExample)
EA (1) EA201391331A1 (enExample)
HK (1) HK1198173A1 (enExample)
MA (1) MA35385B1 (enExample)
MX (1) MX2013010497A (enExample)
PE (1) PE20140593A1 (enExample)
PH (1) PH12013501865A1 (enExample)
SG (2) SG10201601789TA (enExample)
TW (1) TW201300407A (enExample)
UY (1) UY33959A (enExample)
WO (1) WO2012125973A2 (enExample)
ZA (1) ZA201306920B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636418B2 (en) 2013-03-12 2017-05-02 Amgen Inc. Potent and selective inhibitors of NAV1.7
US10344060B2 (en) * 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
DK2968495T3 (da) * 2013-03-15 2019-10-14 Daniel J Capon Hybrid immunoglobulin indeholdende en ikke-peptid-bro
LT3116486T (lt) 2014-03-14 2020-04-10 Biomolecular Holdings Llc Hibridinis imunoglobulinas, turintis nepetidilinę jungtį
KR101981532B1 (ko) * 2014-06-12 2019-09-02 라 파마슈티컬스 인코포레이티드 보체 활성의 조절
CN105348392B (zh) * 2015-11-18 2019-08-02 北京华金瑞清生物医药技术有限公司 一种Nav1.7抑制剂及其改造方法
US20170239183A1 (en) * 2016-02-23 2017-08-24 PixarBio Corporation COMPOSITIONS COMPRISING NAv1.7 SELECTIVE INHIBITORS FOR TREATING ACUTE, POST-OPERATIVE, OR CHRONIC PAIN AND METHODS OF USING THE SAME
EP3512870B1 (en) * 2016-09-16 2022-08-03 Olipass Corporation Scn9a antisense oligonucleotides
RU2762293C2 (ru) * 2017-01-24 2021-12-17 Олипасс Корпорейшн Антисмысловое для scn9a обезболивающее средство
CN109517041B (zh) * 2018-11-14 2019-09-17 青海芬陀利华生物科技有限公司 Gptx-1毒素及其应用
CN116234920A (zh) * 2020-08-05 2023-06-06 国立研究开发法人产业技术总合研究所 作用于靶蛋白的多肽的筛选方法
US20230374084A1 (en) 2020-09-23 2023-11-23 Aldevron, Llc Potent and selective inhibitors of nav1.7
CN113429463B (zh) * 2021-05-18 2022-08-23 湖南百尔泰克生物医药有限公司 一种具有镇痛作用的多肽及其应用
CN114805491B (zh) * 2022-03-15 2025-10-03 青岛海洋生物医药研究院 一种芋螺毒素kiiia突变体及其制备方法和应用
CN114805492B (zh) * 2022-03-15 2025-07-22 上海元炘执药科技有限公司 一种用于抑制电压门控钠离子通道1.4的芋螺毒素kiiia突变体及其制备方法和应用
CN114917324B (zh) * 2022-04-22 2025-05-30 江苏好上医生物医药有限公司 一种含虎纹毒素-iv的药物组合物及其应用
KR20250005373A (ko) 2022-04-22 2025-01-09 버텍스 파마슈티칼스 인코포레이티드 통증 치료를 위한 헤테로아릴 화합물
EP4511115A1 (en) 2022-04-22 2025-02-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
EP4511114A1 (en) 2022-04-22 2025-02-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2023255558A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CN120603815A (zh) 2022-12-06 2025-09-05 沃泰克斯药物股份有限公司 钠通道的取代四氢呋喃调节剂的合成方法
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
TW202523313A (zh) 2023-10-23 2025-06-16 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
TW202535867A (zh) 2023-10-23 2025-09-16 美商維泰克斯製藥公司 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
US20250163168A1 (en) 2023-11-17 2025-05-22 Pfizer Inc. Novel antibodies and antibody conjugates for the treatment of metabolic disorders
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025230491A1 (en) * 2024-04-30 2025-11-06 Vsy Biyoteknoloji Ve Ilac Sanayi Anonim Sirketi A formulation for the treatment of interstitial cystitis disorder in particular

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4351337A (en) 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4083368A (en) 1976-09-01 1978-04-11 Freezer Winthrop J Inhaler
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US5002936A (en) 1985-04-12 1991-03-26 Seymour Lieberman Lipophilic complexes of pharmacologically active inorganic mineral acid esters of organic compounds
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
AU607172B2 (en) 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
US4906169A (en) 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4983395A (en) 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
DE68925893T2 (de) 1988-07-23 1996-08-08 Delta Biotechnology Ltd Sekretorische leader-sequenzen
US4925677A (en) 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5171264A (en) 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ES2199935T3 (es) 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
JPH0640945A (ja) 1992-07-23 1994-02-15 Kureha Chem Ind Co Ltd Ｆｃフラグメント結合抗腫瘍剤
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5432155A (en) 1993-06-29 1995-07-11 The Salk Institute For Biological Studies Conotoxins I
US5514774A (en) 1993-06-29 1996-05-07 University Of Utah Research Foundation Conotoxin peptides
US5460820B1 (en) 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
AU1843295A (en) 1994-02-23 1995-09-11 Chiron Corporation Method and compositions for increasing the serum half-life of pharmacologically active agents
FR2717688B1 (fr) 1994-03-28 1996-07-05 Lhd Lab Hygiene Dietetique Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA.
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CN1170360A (zh) 1994-12-21 1998-01-14 瑟垃技术有限公司 具有粘性贴面和剥离密封圆片的经皮输送系统
DE69530325T2 (de) 1994-12-22 2004-02-19 Astrazeneca Ab Aerosol-arzneiformulierungen
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5776896A (en) 1996-01-03 1998-07-07 Zeneca Limited Analgesic peptides from venom of grammostola spatulata and use thereof
US5756663A (en) 1996-01-03 1998-05-26 Zeneca Limited Antiarrhythmic peptide from venom of spider Grammostola spatulata
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US6077680A (en) 1996-11-27 2000-06-20 The University Of Florida ShK toxin compositions and methods of use
DE69734451T2 (de) 1996-12-26 2006-07-13 Suntory Limited Skorpion-spezifische neuropeptide
WO2000055371A1 (en) 1999-03-18 2000-09-21 Human Genome Sciences, Inc. 27 human secreted proteins
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
JP3530004B2 (ja) 1998-02-06 2004-05-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
US6022952A (en) 1998-04-01 2000-02-08 University Of Alberta Compositions and methods for protein secretion
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
AUPP589598A0 (en) 1998-09-14 1998-10-08 University Of Queensland, The Novel peptides
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1132479B1 (en) 1998-11-20 2009-04-22 Fuso Pharmaceutical Industries Ltd. Protein expression vector and utilization thereof
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
KR100491815B1 (ko) 1998-12-23 2005-05-27 암젠 인코포레이티드 단백질의 서방성 수송을 위한 폴리올/오일 현탁액을 포함하는 제약학적 조성물 및 그것의 제조방법
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2001038564A2 (en) 1999-11-26 2001-05-31 Mcgill University Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
CA2393616A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
SE0000935D0 (sv) 2000-03-21 2000-03-21 Astrazeneca Ab An inhalation device
US7125847B1 (en) 2000-04-07 2006-10-24 The Research Foundation Of State University Of New York At Buffalo Mechanically activated channel blocker
CN1133461C (zh) 2000-04-11 2004-01-07 厦门北大之路生物工程有限公司 虎纹捕鸟蜘蛛毒素提取物在制备镇痛药物中的应用
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
EP1280895B1 (en) 2000-05-10 2005-08-03 Centre National De La Recherche Scientifique (Cnrs) Polypeptide inhibiting a proton-gated na+ channel
EP1177806A1 (en) 2000-08-04 2002-02-06 The Technology Partnership Public Limited Company Dry powder inhaler
GB0021617D0 (en) 2000-09-02 2000-10-18 Imp College Innovations Ltd Diagnosis and treatment of cancer
JP5013152B2 (ja) 2001-02-28 2012-08-29 株式会社ビーエムジー 蛋白質複合体形成剤
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
US20050054051A1 (en) 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
CA2443968A1 (en) 2001-04-12 2002-10-24 Imperial College Innovations Limited Diagnosis and treatment of cancer: i
GB0120238D0 (en) 2001-08-20 2001-10-10 Univ College Of London Sodium channel regulators and modulators
US6887487B2 (en) 2001-10-19 2005-05-03 Idexx Laboratories, Inc. Injectable compositions for the controlled delivery of pharmacologically active compound
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
US7125676B2 (en) 2002-02-25 2006-10-24 Vanderbilt University Expression system for human brain-specific voltage-gated sodium channel, type 1
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
ATE469135T1 (de) 2002-05-30 2010-06-15 Scripps Research Inst Kupferkatalysierte ligierung von aziden und acetylenen
GB0219512D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
ATE447025T1 (de) 2003-03-26 2009-11-15 Pharmadesign Inc Ionenkanalaktivität hemmende niedrigmolekulare peptide
ES2298785T3 (es) 2003-06-12 2008-05-16 Eli Lilly And Company Proteinas de fusion.
AR045445A1 (es) 2003-08-05 2005-10-26 Vertex Pharma Compuestos ihinibidores de canales ionicos regulados por voltaje
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
TW200524888A (en) 2003-08-08 2005-08-01 Vertex Pharma Compositions useful as inhibitors of voltage-gated ion channels
US7125908B2 (en) 2003-08-29 2006-10-24 Allergan, Inc. Treating pain using selective antagonists of persistent sodium current
US7060723B2 (en) 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
AU2005207002B2 (en) 2004-01-21 2011-03-17 University Of Utah Research Foundation Mutant sodium channel Nav1.7 and methods related thereto
WO2005118614A1 (en) 2004-04-08 2005-12-15 Avigen, Inc. Methods and compositions for treating neuropathic pain
US7323169B2 (en) 2004-04-23 2008-01-29 Amgen Inc. Sustained release formulations
CN1973404B (zh) 2004-06-23 2011-06-08 胡贝尔和茹纳股份公司 宽带贴片天线
GB0414272D0 (en) 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
US7259145B2 (en) 2004-07-07 2007-08-21 The Research Foundation Of State University Of New York Mechanically activated channel blocker
WO2006036834A2 (en) 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
EP1796709A4 (en) 2004-10-07 2009-10-28 Univ California ANALOGUES OF TOXIN SHK AND USES IN SELECTIVE INHIBITION OF KV1.3 POTASSIUM CHANNELS
JP2008519034A (ja) 2004-11-03 2008-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネル調節剤としてのピリミジン誘導体および使用方法
US20060199812A1 (en) 2005-01-24 2006-09-07 Amgen Inc. Method of conjugating aminothiol containing molecules to vehicles
US7531523B2 (en) 2005-02-17 2009-05-12 Vertex Pharmaceuticals Incorporated Sodium channel protein type III alpha-subunit splice variant
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
GB0517487D0 (en) 2005-08-26 2005-10-05 Isis Innovation Antibodies
US7972813B2 (en) 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
JP2009514545A (ja) 2005-11-08 2009-04-09 アテリス ラボラトリーズ μ−コノトキシンぺプチドおよびμ−コノトキシンぺプチドの局所麻酔薬としての使用
WO2007109324A2 (en) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers
EP2628749A3 (en) 2006-06-20 2013-12-04 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Antimicrobial kinocidin compostions and methods of use
JP4742345B2 (ja) * 2006-06-20 2011-08-10 独立行政法人産業技術総合研究所 カルシウムチャネルを遮断するグラモストラ・スパチュラタ由来のポリペプチドおよびその遺伝子
WO2008088422A2 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
WO2009033027A2 (en) 2007-09-05 2009-03-12 Medtronic, Inc. Suppression of scn9a gene expression and/or function for the treatment of pain
CN101480393A (zh) * 2008-01-07 2009-07-15 云南昊邦制药有限公司 草乌甲素作为制备治疗Nav1.7疼痛病症药物的应用
EP2249856B1 (en) 2008-01-30 2013-11-06 Baylor College Of Medicine Peptides that target dorsal root ganglion neurons
BRPI0924225A2 (pt) 2009-02-02 2016-10-11 Chromocell Corp linhagens de células que expressam nav e métodos de uso
WO2010104114A1 (ja) * 2009-03-10 2010-09-16 独立行政法人産業技術総合研究所 ポリペプチドライブラリーを調製する方法
WO2010104115A1 (ja) 2009-03-10 2010-09-16 独立行政法人産業技術総合研究所 膜タンパク質を特異的に認識するポリペプチドの調製方法
CA2755133A1 (en) 2009-03-20 2010-09-23 Amgen Inc. Selective and potent peptide inhibitors of kv1.3
JP5555891B2 (ja) 2009-09-15 2014-07-23 アロモネ プリクリニカル リミテッド クモ毒から単離した新規ペプチド及びその使用
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
WO2011051350A1 (en) 2009-10-27 2011-05-05 Ucb Pharma S.A. Function modifying nav 1.7 antibodies
US8871996B2 (en) 2010-06-09 2014-10-28 Regeneron Pharmaceuticals, Inc. Mice expressing human voltage-gated sodium channels
US9279003B2 (en) 2010-07-07 2016-03-08 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
EP2852397B1 (en) 2012-05-18 2022-02-16 Janssen Biotech, Inc. Huwentoxin-iv variants and methods of use

Also Published As

Publication number Publication date
KR20140145947A (ko) 2014-12-24
HK1198173A1 (en) 2015-03-13
US9796766B2 (en) 2017-10-24
CL2013002673A1 (es) 2014-07-25
TW201300407A (zh) 2013-01-01
CA2830065A1 (en) 2012-09-20
PE20140593A1 (es) 2014-05-10
CN103930437A (zh) 2014-07-16
BR112013023674A2 (pt) 2016-12-13
US20140073577A1 (en) 2014-03-13
NZ615242A (en) 2016-03-31
SG193434A1 (en) 2013-10-30
AU2012228990B2 (en) 2017-04-06
JP2014509859A (ja) 2014-04-24
AR088413A1 (es) 2014-06-11
US20160304570A1 (en) 2016-10-20
CO6821886A2 (es) 2013-12-31
AU2012228990A1 (en) 2013-09-19
ZA201306920B (en) 2014-05-28
EP2686340A2 (en) 2014-01-22
MA35385B1 (fr) 2014-09-01
SG10201601789TA (en) 2016-04-28
WO2012125973A2 (en) 2012-09-20
US9340590B2 (en) 2016-05-17
UY33959A (es) 2012-09-28
WO2012125973A3 (en) 2013-01-03
EA201391331A1 (ru) 2014-02-28
PH12013501865A1 (en) 2014-01-06
MX2013010497A (es) 2013-12-16
JP2017031157A (ja) 2017-02-09
AP2013007173A0 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
CR20130533A (es) INHIBIDORES POTENTES Y SELECTIVOS DE NAv1.3 y NAv1.7
MX2022007527A (es) Inhibidores de proteinas kras mutantes.
CR20140450A (es) Composicion para el control de plagas que incluye un derivado de iminopiridina novedoso
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
AR087113A1 (es) Metodo de cementado y composicion
MX2014000518A (es) Inhibidores de la tirosina quinasa de bruton.
BR112014012543A2 (pt) métodos e materiais para síntese enzimática de compostos de mogrosídeo
CO6531429A2 (es) Inhibidores de la tirosina quinasa de bruton
MX336875B (es) Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
GT201400012A (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
CR20150412A (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa pim
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
PH12015501057A1 (en) Positive working photosensitive material
NI201001031A (es) Formas cristalinas de dimetoxi docetaxel y metodo para preparar el mismo.
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
GT201400014A (es) Biocontrol de nematodos
UY33930A (es) Inhibidores novedosos de quinasas
UY34537A (es) Composiciones y métodos para anticuerpos que actúan sobre el factor p
DOP2014000098A (es) 2-tiopirimidinonas
CR20140128A (es) Inhibidores de la enzima activadora de nedd 8
AR099500A1 (es) Composición para el desmucilaginado enzimático de aceite
UY35397A (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
MX2015003039A (es) Proceso para la reducción de derivados nitro a aminas.
CR20160066A (es) Compuestos y métodos para mejorar el rendimiento de una planta
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina